Fundraising Fox
GeneCentric
Durham, US · Founded 2011 · 14 employees on LinkedIn · 2 known investors
Find your way into GeneCentric
Sign up to see every warm intro you have to GeneCentric
- Paths you didn't know you had: your email and LinkedIn already hold routes to the GeneCentric team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
A biotech company offering gene expression analysis tools for blood-based biomarker detection across multiple cancer types. The company develops molecular signatures and liquid biopsy solutions for biopharma, diagnostics, and CRO partners.
Founders & leadership
GeneCentric was founded in 2011 by Charles M. Perou.
CM
Charles M. PerouFounder and DirectorCharles M. Perou holds a PhD in Experimental Pathology from the University of Utah and conducted postdoctoral research with David Botstein at Stanford University. He has spent over two decades studying cancer genomics and molecular subtypes, particularly in breast cancer research, and co-founded GeneCentric Therapeutics to develop genomic assays and molecular signatures for personalized cancer diagnostics.
MM
MICHAEL MILBURNCEO and PresidentMichael Milburn is an executive and scientist with over 20 years in biotechnology leadership at companies including Plexxikon, Sirtris Pharmaceuticals, Metabolon, and GeneCentric Therapeutics, with published research in drug design, computational biology, metabolomics, and genomics.
DN
David Neil HayesNamed on SEC filing
Board
CT
ML
AL
Arnold LevineBoard director
PR
Prasanth ReddyBoard director
DH
Don HardisonBoard director
Investors · 2
Hatteras Venture Partners✓ confirmed by GeneCentricResearch Triangle · $500K – $4M
How we know: Hatteras Venture Partners's portfolio page · the company's own site · a partner's Signal profile · board seat on SEC Form D · funding news · the VCSheet dataset · Not right? Tell us
IAG Capital PartnersreportedCharleston
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$21.3M disclosed across 6 rounds · 2013–2025
▶$2MraisedJun 2025 · 9 investors · BiotechnologyRule 506(b)
▶$2MraisedJun 2025 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CLAY THORPDirector
- MICHAEL MILBURNExecutive Officer, Director
- ARNOLD LEVINEDirector
- CHARLES PEROUDirector
- Prasanth ReddyDirector
- MYLA LAI-GOLDMANDirector
- Don HardisonDirector
- Offering amount
- $5M
- Amount sold
- $2M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedSep 2022 · 1 investors · BiotechnologyRule 506(b)
▶$2.5MraisedSep 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- ARNOLD LEVINEDirector
- CLAY THORPDirector
- CHARLES PEROUDirector
- MYLA LAI-GOLDMANDirector
- ELLEN LUBMANDirector
- MICHAEL MILBURNExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $2.5M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedOct 2021 · 1 investors · BiotechnologyRule 506(b)
▶$4.5MraisedOct 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ellen LubmanDirector
- Michael V. MilburnExecutive Officer, Director
- Perou CharlesExecutive Officer, Director
- Clay ThorpDirector
- Myla Lai-GoldmanExecutive Officer, Director
- Arnold LevineDirector
- Offering amount
- $7.5M
- Amount sold
- $4.5M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.2MraisedJan 2021 · 4 investors · BiotechnologyRule 506(b)
▶$1.2MraisedJan 2021 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles PerouExecutive Officer, Director
- Arnold LevineDirector
- Clay ThorpDirector
- Michael MilburnExecutive Officer, Director
- Myla Lai-GoldmanExecutive Officer, Director
- Ellen LubmanDirector
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.1MraisedJan 2017 · 4 investors · BiotechnologyRule 506(b)
▶$6.1MraisedJan 2017 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Myla Lai-GoldmanExecutive Officer, Director
- Clay ThorpDirector
- Arnold LevineDirector
- David Neil HayesExecutive Officer, Director
- Charles PerouDirector
- Offering amount
- $8.6M
- Amount sold
- $6.1M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedJul 2014 · 4 investors · BiotechnologyRule 506(b)
▶$5MraisedJul 2014 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles PerouDirector
- Myla Lai-GoldmanExecutive Officer, Director
- Arnold LevineDirector
- David Neil HayesExecutive Officer, Director
- Clay ThorpDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Jun 2013
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as GeneCentric.
In the news
Frequently asked questions
- What does GeneCentric do?
- A biotech company offering gene expression analysis tools for blood-based biomarker detection across multiple cancer types. The company develops molecular signatures and liquid biopsy solutions for biopharma, diagnostics, and CRO partners.
- Who founded GeneCentric?
- GeneCentric was founded by Charles M. Perou in 2011.
- Who are GeneCentric's investors?
- GeneCentric's investors include Hatteras Venture Partners, IAG Capital Partners.
- How much funding has GeneCentric raised?
- GeneCentric has disclosed $21.3M raised across 6 rounds.
- Where is GeneCentric headquartered?
- GeneCentric is headquartered in Durham, US.